Bioprocessing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Products (Instruments (Bioprocess Analyzers, Gas Analyzers, Osmometers, Cell Counter Systems, Bioreactors, and Incubators), Consumables &Accessories (Culture Media, and Reagents)), By End-Users (Biotechnology & Biopharmaceutical Companies, Research & Academic Institutes, Others), and Region

Bioprocessing Market size was valued at US$ 23,829.1 million in 2023 and is poised to grow at a CAGR of 13.6% from 2024-2030. Bioprocess technology is concerned with the development of machinery and processes for using biological sources of raw materials to produce goods including chemicals, polymers, food, feed, pharmaceuticals, and nutraceuticals. Bioprocessing, which includes designing bioreactors, biocatalysts, substrate and media volume production, downstream processing, and purification, is an amalgamation of biology, mathematics, and engineering. The market has been growing over the past few years due to the usage of bioprocess technology in the production of biosimilar and biopharmaceutical goods. Also, key factors fuelled in the market are an increase in infectious disease cases and ongoing advancements in bioprocessing technology, growing demand for biologics, rising prevalence of chronic diseases, and increased investment in research and development with regulatory compliance.

For instance, The Telangana government's flagship biotech and pharmaceutical event, BioAsia 2017, brought in around 507.3 million US$ in investment. At the Gujarat Global Summit that same year, 37 firms signed sector agreements related to biotechnology. However, the high costs of bioprocessing equipment, complexity of bioprocessing techniques, regulatory challenges, supply chain issues, and risk of contamination are the limiting factors for the market growth. Furthermore, the development of advanced therapies, integration of AI and data analytics, personalized medicine, and sustainability initiatives are opportunities for the market. In addition, single-use technologies, continuous bioprocessing, automation, digitalization, increased focus on quality by design, and regenerative medicine with tissue engineering are the major trends in the market.

Key Developments

• In February 2024, Together, Cytiva and LevitasBio have developed a cutting-edge single-cell process for academic and commercial genomics researchers.
• In Febuary 2024, Thermo Fisher Scientific Inc. declared that it will be expanding its St. Louis manufacturing facility to facilitate the production of biological therapies for uncommon illnesses. With the expansion, the business has doubled the amount of biologics it can manufacture for complex biologic treatments. It plans to increase production from 2,000 to 5,000 liters per year for diseases like cancer, autoimmune disorders, and uncommon illnesses